Author:
Rodseeda Chumaphorn,Yamanont Paveena,Pinthong Darawan,Korprasertthaworn Porntipa
Subject
Health, Toxicology and Mutagenesis,Toxicology
Reference49 articles.
1. Role of tyrosine kinase inhibitors in cancer therapy;Arora;J. Pharmacol. Exp. Ther.,2005
2. FDA, 2003. Drug approval package: Iressa (gefitinib) NDA #021399. 〈https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021399_iressa.cfm/〉 (Accessed 26 April 2020).
3. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes;Li;Clin. Cancer Res.,2007
4. In vitro metabolism of gefitinib in human liver microsomes;McKillop;Xenobiotica,2004
5. FDA, 2007a. Drug approval package: Tykerb (lapatinib) NDA #022059. 〈https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022059s000TOC.cfm/〉 (Accessed 31 May 2021).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献